GC Green Cross Varicella Vaccine Strain 'MAV/06' Listed in WHO Guidelines

Securing Global Supply Stability and Anticipating Business Expansion

GC Green Cross announced on December 2 that its varicella vaccine strain, MAV/06, has been listed in the WHO Position Paper. The WHO Position Paper is the most authoritative guideline document that sets global public health policies and vaccination recommendations. It is published after review by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization.

GC Green Cross

With this listing, GC Green Cross's MAV/06-based varicella vaccine, Varicellavax, has received international recognition equivalent to the OKA-based global varicella vaccines supplied by multinational pharmaceutical companies.

In particular, the document officially recognizes the interchangeability of MAV/06-based and OKA-based vaccines, allowing Varicellavax to be used in combination with existing global vaccines during the two-dose varicella vaccination process without any issues. This establishes a foundation for stable substitution even if there are fluctuations in the supply of a specific strain, which is expected to significantly enhance global vaccine supply stability and the health response capabilities of each country.

Based on this international status, GC Green Cross expects to further strengthen its position in the global procurement market operated by the Pan American Health Organization (PAHO).

The company also added that the increased international credibility of domestic regulatory authorities contributed positively to this achievement. In August, the Ministry of Food and Drug Safety became the first in the world to be listed in all areas as a WHO Listed Authority, greatly elevating its status.

Lee Jaewoo, Head of Development at GC Green Cross, stated, "The inclusion of the MAV/06 strain in the WHO Position Paper is a significant milestone for the stabilization of global varicella vaccine supply," adding, "We will strengthen our supply system to meet global demand, leveraging GC Green Cross’s ample production capacity."

Meanwhile, MAV/06, developed independently by GC Green Cross in 1993, has been supplied to several countries for about 30 years under the product names Varicellavax and Varicellaju.

This content was produced with the assistance of AI translation services.